登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>VEGF R1 >VE1-H82E3

Biotinylated Human VEGF R1 / Flt-1 Protein, His,Avitag™

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

FLT,VEGFR1,FLT1

表达区间及表达系统(Source)

Biotinylated Human VEGF R1, His,Avitag (VE1-H82E3) is expressed from human 293 cells (HEK293). It contains AA Ser 27 - Asn 756 (Accession # P17948-1 ).

Predicted N-terminus: Ser 27

Request for sequence

蛋白结构(Molecular Characterization)

VEGF R1 Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)

The protein has a calculated MW of 85.9 kDa. The protein migrates as 106-125 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

VEGF R1 SDS-PAGE

Biotinylated Human VEGF R1, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

VEGF R1 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) with a linear range of 1-31 ng/mL (QC tested).

Protocol

VEGF R1 ELISA

Immobilized Human PLGF, His Tag (Cat. No. PGF-H5229) at 1 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) with a linear range of 2-20 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

VEGF R1 BLI

Loaded Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) on SA Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 0.236 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Vascular endothelial growth factor receptor 1 (VEGFR1) is also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
VEGF R1靶点信息
英文全称:Vascular endothelial growth factor receptor 1
中文全称:血管内皮细胞生长因子受体1
种类:Homo sapiens
上市药物数量:12详情
临床药物数量:19详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定